Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
888 An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity
Compose a Response to This Article
Other responses
No responses have been published for this article.